ADAR1 Capital Management’s Royalty Pharma RPRX Stock Holding History

ADAR1 Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$701K	Buy	12,500 +7,500	+150%	+$390K	0.03%	189
2026 Q1	$240K	Buy	+5,000	New	+$219K	0.01%	252
2025 Q1	–	Sell	-49,963	Closed	-$1.27M	–	245
2024 Q4	$1.27M	Sell	49,963 -1,046,703	-95%	-$27.8M	0.25%	69
2024 Q3	$31M	Sell	1,096,666 -84,666	-7%	-$2.35M	5.05%	7
2024 Q2	$31.2M	Buy	1,181,332 +460,031	+64%	+$12.8M	5.88%	6
2024 Q1	$21.9M	Sell	721,301 -600,533	-45%	-$17.7M	4.97%	9
2023 Q4	$37.1M	Buy	+1,321,834	New	+$36.3M	13.27%	2

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ADAR1 Capital Management's RPRX Position: Q2 2026 in Review

ADAR1 Capital Management increased its Royalty Pharma (RPRX) stake by 150% in Q2 2026, buying an estimated $390K and bringing the position to 12,500 shares worth $701K. The position accounts for 0.03% of the portfolio, ranked #189.

ADAR1 Capital Management first reported a position in RPRX in Q4 2023 and has held it in 7 quarters since. The position peaked at $37.1M in Q4 2023. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

ADAR1 Capital Management held 12,500 shares of Royalty Pharma worth $701K as of Q2 2026.
ADAR1 Capital Management bought 7,500 Royalty Pharma shares in Q2 2026, an estimated $390K.
Royalty Pharma made up 0.03% of ADAR1 Capital Management's portfolio in Q2 2026, its #189 holding.
ADAR1 Capital Management first reported a position in Royalty Pharma in Q4 2023 and has held it in 7 quarters since.
ADAR1 Capital Management's Royalty Pharma position peaked at $37.1M in Q4 2023.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.